The aim of the study is to evaluate the predictors of success of oral dissolution therapy in radiolucent renal stones in a large series of patients from a tertiary referral center in order to define the optimum case scenarios where oral dissolution therapy could be implemented.
Patients with renal stones, seen through the outpatient clinic in the urology department or post primary intervention for renal stones, will be assessed to see if the patient satisfies all inclusion and exclusion criteria. Patients who are meeting these criteria will be asked to participate in this prospective study. If they agree, they will be asked to sign an informed consent. Baseline patients' assessment will include; * Full history taking including * Previous stone history regarding presentation and management * Previous trial oral dissolution therapy for renal stones and their compliance to the treatment * Previous GIT surgery * History of chronic medical or metabolic illness e.g; DM * Clinical examination including o Body mass index (BMI) * Laboratory investigations including; * Urine analysis (urine PH) * 24 hours urine testing for uric acid and citrate * Urine culture * Serum creatinine * Random blood sugar (RBS) * Serum uric acid * Serum calcium, phosphorus and magnesium. * Initial radiological evaluation will include * Renal ultrasonography (US) * Plain X-rays to exclude the presence of calcification in the targeted stone. * Non Contrast Computed Tomography (NCCT) on the abdomen and pelvis. * MAG3 diuretic renogram (All NCCT studies will be performed with multislice helical CT scanners, NCCT images will be obtained from above the kidneys through the bladder base. For each renal stone, its location will be recorded, its size will be measured using the largest dimension from length (L), width (W) and height (H) on axial and coronal reformat images. Its mean density will be recorded by measurement using region of interest just smaller than the stone. Associated hydronephrosis proximal to the stone will be also evaluated (Nakada et al 2000).) Patient will receive the allocated instructions and medications Patients' follow up (The aim at follow up is to monitor the urinary PH with adjustment of the dose of potassium citrate and also to assess the compliance of the patients regarding the dietary recommendations and the medications) * After 2 weeks, 4 weeks, 8 weeks and 12 weeks. \- the most important parameter will be assessed is the urinary PH every two weeks. The target urinary PH should be kept between6.5 to 7.0, the dose of potassium citrate should be adjusted to achieve this value. * Patients' compliance to medications intake and the instruction of fluid intake and dietary modification.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
182
Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy * Potassium citrate 20 mEq three times daily * Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive: Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily.
Eligible patients, who fulfilled the study criteria, will be also instructed for; Adequate fluid intake in order to maintain urine volume between 2-3 L per day.
Urology and Nephrology Center
Al Mansurah, DK, Egypt
The primary endpoint of this study will be change in stone surface area after 3 months of the determined protocol
The stone surface area will be measured using the formula; Surface area = length X width X 0.25 X (22/7) Comparison of the stone surface area in relation to the initial surface area will be done.
Time frame: participants will be followed for the duration of medical treatment which is specified to be 3 months
Assessment of the predictors of response (more than 50% reduction in the surface area of the stone) to medical treatment
The percent reduction of stone surface area will be calculated using the formula: Surface area = length X width X 0.25 X (22/7) Categorization of the patients into three groups will be done: * Patients who achieved 50% or more reduction in the stone surface area will be considered responsive and would be counseled for another 3 months therapy. * Patients with partial response, less than 50% reduction in stone surface area will be counseled for auxiliary procedure based on stone criteria e.g. ESWL. * Patients with no response/ serious renal infections or serious treatment adverse effects will be considered for other interventional treatment modalities. In the responders groups, factors predicting the success of treatment will be determined
Time frame: participants will be followed for the duration of medical treatment which is specified to be 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.